Additionally, tinengotinib displayed robust antitumor activity and achieved 80% TGI in the CC6204 PDX FGFR2-BICC1 gene fusion model (Supplementary Fig. S4), suggesting its potential clinical application in patients with FGFR2 fusion-positive cholangiocarcinoma. This evidence concerns the gene BICC1 and cholangiocarcinoma.